Baroda BNP Paribas Dividend Yield Fund
Direct · GrowthAI Summary
The Baroda BNP Paribas Dividend Yield Fund delivered a 1Y SIP XIRR of 5.14%, well below the category average of 15.59%, indicating significant underperformance against dividend yield peers. However, it has outperformed the NIFTY 50 on a lump-sum basis, with a 1Y Fund CAGR of 5.93% versus the benchmark's -2.90%, generating a strong alpha of 7.54%. Over longer horizons (7Y-15Y), alpha turns marginally negative, suggesting the benchmark outperformance is a recent phenomenon.
The fund exhibits low volatility characteristics with a maximum drawdown of just -0.18% and only one drawdown event exceeding 10%, reflecting its defensive dividend yield mandate. A beta of 0.86-0.89 with a downside capture of 81.61% (1Y) confirms it falls less than the market in downturns, while upside capture of 92.73% shows modest participation in rallies. The 1Y Calmar ratio of 0.26 indicates modest risk-adjusted returns, and the 154-day drawdown duration without full recovery warrants monitoring.
The fund holds 41 stocks with a well-diversified top 10 accounting for roughly 41% of NAV, led by Reliance Industries (6.61%), ICICI Bank (5.26%), and HDFC Bank (5.14%). Sector allocation is balanced, with Banks (16.1%) and Pharmaceuticals (13.7%) as the largest exposures, followed by IT, Petroleum, and Auto Components. The meaningful pharma weighting (Torrent Pharma, Divi's Labs, Sun Pharma, GSK Pharma) reinforces the defensive, dividend-focused character of the portfolio.
The fund trails its category substantially on SIP XIRR across all periods, with a 1Y XIRR of 5.14% versus the category average of 15.59% — a gap of over 10 percentage points. Its consistent alpha over the NIFTY 50 in the 1Y and 3Y windows is a positive, but the near-zero and negative alpha beyond 7 years suggests limited long-term edge over the broad market. Calendar year returns have been uneven, ranging from -6.63% in 2024 to 7.05% in 2025.
This fund suits conservative equity investors seeking lower volatility and downside protection rather than aggressive growth, given its low beta and strong downside capture metrics. A time horizon of at least 5-7 years is advisable, as long-term returns have been modest and the fund needs extended periods to demonstrate its defensive compounding. Investors should have moderate risk tolerance and accept that in strong bull markets the fund will likely lag the broader index due to its 92.73% upside capture.
- Strong 1Y alpha of 7.54% over the NIFTY 50, with the fund gaining 5.93% while the benchmark declined 2.90%
- Low downside capture of 81.61% and beta of 0.86, offering meaningful protection during market declines
- Diversified 41-stock portfolio with balanced sector exposure led by defensive Banks and Pharmaceuticals
- 1Y SIP XIRR of 5.14% is far below the category average of 15.59%, indicating underperformance versus dividend yield peers
- Alpha turns negative over 7Y-15Y horizons (e.g., -0.41% at 15Y), showing no long-term outperformance versus the NIFTY 50
Generated on 09-09-2026, 3:34 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.29 L | 5.1% | -15.1% | 17.2% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 5.1% | 14.4% | 15.6% | -9.3% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 4.7% | 4.5% | -7.1% | 17.1% | -0.36 | -0.39 | 84% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +7.54 | 0.86 | 92.7% | 81.6% | 5.9% | -2.9% |
| 3 Years | +0.94 | 0.89 | 91.6% | 88.1% | 0.2% | -1.7% |
| 5 Years | +0.27 | 0.89 | 91.6% | 88.1% | 0.1% | -1.0% |
| 7 Years | -0.02 | 0.89 | 91.6% | 88.1% | 0.1% | -0.7% |
| 10 Years | -0.23 | 0.89 | 91.6% | 88.1% | 0.1% | -0.5% |
| 12 Years | -0.32 | 0.89 | 91.6% | 88.1% | 0.1% | -0.4% |
| 15 Years | -0.41 | 0.89 | 91.6% | 88.1% | 0.0% | -0.3% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Reliance Industries Limited | 6.36% |
| 2 | ICICI Bank Limited | 5.50% |
| 3 | Larsen & Toubro Limited | 4.63% |
| 4 | HDFC Bank Limited | 4.41% |
| 5 | Torrent Pharmaceuticals Limited | 4.16% |
| 6 | GE Vernova T&D India Limited | 3.76% |
| 7 | GlaxoSmithKline Pharmaceuticals Limited | 3.28% |
| 8 | Divi's Laboratories Limited | 3.24% |
| 9 | Radico Khaitan Limited | 3.04% |
| 10 | Hero MotoCorp Limited | 2.70% |